Drugs / Phenlarmide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04693039 | Feb → Oct 2021 | Parkinson disease | Shijiazhuang Yiling Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04164121 | Dec 2019 → Dec 2020 | Parkinson disease | Yiling Pharmaceutical Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Phenlarmide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04164121 ↗ |
| Route | Oral | “Oral administration was conducted on an empty stomach” NCT04164121 ↗ |